{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T21:48:08Z","timestamp":1782078488937,"version":"3.54.5"},"reference-count":27,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pomalidomide (POM) can cause skin rash, although it is generally considered less frequent than lenalidomide (LEN)-induced rash. However, skin rash remains a clinically relevant adverse event that may lead to treatment interruption in patients with multiple myeloma. This study aimed to identify clinical risk factors for POM-induced skin rash.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 76 patients who received POM-containing regimens between 2015 and 2022. The incidence, severity, and timing of skin rash were evaluated. Clinical variables were compared between patients with and without POM-induced skin rash, and multivariate logistic regression was performed to identify independent risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>POM-induced skin rash occurred in 22.4% of patients, with 17.1% experiencing Grade \u22652 rash. Treatment interruption due to rash occurred in 4 patients. A history of LEN-induced skin rash (p\u2009=\u20090.025) and no recent proteasome inhibitor exposure (p\u2009=\u20090.038) were identified as independent risk factors for POM-induced skin rash.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with a prior history of LEN-induced skin rash or with long intervals since proteasome inhibitor exposure are at increased risk for POM-induced skin rash. Pharmacists should identify these high-risk patients before initiating POM therapy and implement early monitoring and supportive care to prevent unnecessary treatment interruption.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261458307","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:29:42Z","timestamp":1781670582000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics and risk factors for pomalidomide-induced skin rash: Implications for pharmacist-led monitoring in real-world multiple myeloma care"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1274-6558","authenticated-orcid":false,"given":"Tomiyuki","family":"Sugi","sequence":"first","affiliation":[{"name":"Meiji Pharmaceutical University"},{"name":"Department of Pharmacy, Eiju General Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryouta","family":"Kushi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Eiju General Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Homare","family":"Hanai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Eiju General Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Hematology, Eiju General Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yui","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Hematology, Eiju General Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morihiro","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Hematology, Eiju General Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Ishii-Nozawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuropharmacology, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Hagihara","sequence":"additional","affiliation":[{"name":"Department of Hematology, Eiju General Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"National Comprehensive Cancer Network. Multiple myeloma (version 1.2025). Available at: https:\/\/www.nccn.org\/login?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf. [Accessed January 16 2025]"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13227"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0813-1"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30152-4"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32556-5"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805762"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12916"},{"key":"e_1_3_4_10_2","article-title":"Practical management of lenalidomide-related rash","volume":"15","author":"Tinsley SM","year":"2015","unstructured":"Tinsley SM, Kurtin SE, Ridgeway JA, et al. Practical management of lenalidomide-related rash. Clin Lymphoma Myeloma Leuk 2015; 15: S64\u2013S69.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1876867"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.03.006"},{"key":"e_1_3_4_13_2","first-page":"137","article-title":"Successful management of drug-induced skin rash in a relapsed multiple myeloma patient with pomalidomide desensitization","volume":"60","author":"Hagihara M","year":"2019","unstructured":"Hagihara M, Ide S, Ohara S, et al. Successful management of drug-induced skin rash in a relapsed multiple myeloma patient with pomalidomide desensitization. Rinsho Ketsueki 2019; 60: 137\u2013139.","journal-title":"Rinsho Ketsueki"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.66"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.119"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-662320"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0620-4"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.238"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-611426"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13905"},{"key":"e_1_3_4_21_2","first-page":"11","article-title":"A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial","volume":"5","author":"Sunami K","year":"2016","unstructured":"Sunami K, Komeno T, Suzuki K, et al. A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial. Exp Hematol Oncol 2016; 5: 11.","journal-title":"Exp Hematol Oncol"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13918"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13433"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14333"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1608531"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001410"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2015.05.002"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13568"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261458307","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261458307","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261458307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T21:19:22Z","timestamp":1782076762000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261458307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":27,"alternative-id":["10.1177\/10781552261458307"],"URL":"https:\/\/doi.org\/10.1177\/10781552261458307","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"article-number":"10781552261458307"}}